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Summary
QUESTIONS UNDER STUDY: As the burden of cardi-
ovascular disease (CVD) increases globally, its prevention
and risk assessment becomes ever more important. We
thus investigated the longitudinal association of the car-
diovascular risk scores in the population-based cohort
SAPALDIA with carotid intima media thickening (CIMT),
an indicator of sub-clinical disease, and CVD incidence.
METHODS: In 2,832 SAPALDIA participants, the Swiss
and ESC heart risk score (AGLA, SCORE) were calculated
based on 2001 data and CIMT was measured in 2010/
11. We ran multi-level linear regression analyses between
scores and CIMT, stratified for CVD status and gender,
and logistic analyses for doctor-diagnosed CVD incidence.
Path analyses investigated direct and indirect effects on
CIMT.
RESULTS: AGLA and SCORE were positively associated
with increasing CIMT in both healthy and CVD diagnosed
subjects and men and women. Participants in highest risk
categories showed a significant CIMT difference of >0.20
mm compared to the reference risk category (<1%), even
larger in CVD healthy subjects and men. With increasing
risk the odds of CVD incidence increased (Ref. <1%; 10
yr. risk AGLA >10% OR 2.1, >20% OR 3.7). Path analyses
yield risk factors’ direct and indirect effects through blood
pressure.
CONCLUSION: The positive longitudinal association
between risk estimations and CIMT confirms the use of
risk scores in assessing individuals and populations at risk.
Systolic blood pressure appears to be a main pathological
mechanism, underscoring the importance of optimal blood
pressure control and the importance of prevention
strategies of risk factors, indirectly affecting CIMT through
the haemodynamic pathway.
Key words: blood pressure; cardiovascular disease;
cardiovascular risk scores; carotid intima media
thickness; epidemiology; prevention
Introduction
Cardiovascular Disease (CVD) remains the main cause of
global mortality and morbidity. While mortality rates have
decreased in developed countries, largely due to primary
prevention efforts [1, 2], the burden of disease remains high
and is increasing in developing countries [3]. It is in this
context that prevention and good risk assessment tools be-
Figure 1
Flow chart. SAPALDIA – follow-ups and timing of data collection of
cardiovascular risk factors and CIMT assessment.
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come even more important in tackling cardiovascular dis-
ease on a larger scale.
Cardiovascular risk scores allow subjects to be identified
at increased risk of developing disease or suffering a fatal
cardiovascular event [4]. In Europe and Switzerland the
most commonly used scores are the ESC heart risk score
(SCORE) [5], estimating the 10–year risk of a fatal event,
and the AGLA-score, an adaptation of the PROspective
CArdiovascular Münster study PROCAM score [6] by the
Swiss Society of Cardiology (Arbeitsgruppe Lipide und
Atherosklerose) estimating the 10–year risk of morbidity
from cardiovascular disease.
Imaging techniques, such as ultrasound measurements of
carotid intima media thickness (CIMT), have shown their
effectiveness in identifying patients at risk [7, 8] and in
improving the risk stratification [9]. Furthermore, CIMT
is a good population-marker of cardiovascular risk [10,
11]. While some studies have shown cross-sectional asso-
ciations between risk scores and structural and functional
indicators of atherosclerosis [12], longitudinal studies have
observed the long-term impact of cardiovascular risks on
vascular indicators [13–15]. To our knowledge, a confirm-
atory study investigating the long term association of cardi-
ovascular risk scores, commonly used in Switzerland, and
CIMT in a Swiss population has not been performed be-
fore. We thus investigated, using the Swiss Air Pollution
And Lung and heart Disease In Adults cohort
(SAPALDIA), how well the cardiovascular risk scores cal-
culated at SAPALDIA 2 in 2001/02 would identify subjects
with thicker CIMT and incident CVD at SAPALDIA 3 in
2010/11 and thereby present first data on carotid intima
media thickness in a representative Swiss population (fig.
1). Secondly, we investigated the single cardiovascular risk
factor effects on CIMT and analysed the direct and indirect
impact of life-style factors via the haemodynamic path-
ways using path analyses.
Methods
The SAPALDIA Study is a multicentre, population-based
cohort of adults from eight regions of Switzerland. The co-
hort study started in 1991 and has been followed up twice,
in 2001/2002 (SAPALDIA 2) and 2010/2011 (SAPALDIA
3) [16, 17]. SAPALDIA collected detailed data on respirat-
ory and general health, life-style and socio-economic situ-
ation by means of interview-led questionnaires at the study
centre in each survey. In 2001, cardio-metabolic diseases
were added as outcomes of interest, and in turn cardio-
metabolic biomarkers, objectively measured anthropomet-
ric data, blood pressure (BP) and heart rate variability were
assessed. In the second follow-up survey, 2010–2011, se-
quential B-mode ultrasound imaging was performed in
SAPALDIA 3 participants turning 50 years within the same
year or older (n = 3,489). Carotid intima media thickness
was introduced as a main outcome into the third
SAPALDIA cohort assessment to investigate individual
risks, such as physical activity, and environmental risks,
such as air pollution. SAPALDIA complies with the De-
claration of Helsinki and ethical approval has been granted
by the respective Swiss cantonal ethical committees (sup-
plemental file: SAPALDIA funding and acknowledge-
ments). Participants gave written informed consent.
Ultrasound examination at SAPALDIA 3
Carotid ultrasound measurements were conducted in the
SAPALDIA Study centres by trained and certified field
workers under the supervision and technical assistance of
Imagelabonline & Cardiovascular, Amsterdam, and the
Dept. of Sports, Exercise and Health, University of Basel,
who also read and scored the images. The common carotid
arterial (CCA) far wall, 1 cm proximal to the bulb, was
visualised in two angles: longitudinal ear to ear and hori-
zontal view. Images were automatically read by the image
analysis programme DYnamic ARtery Analysis (DYARA)
[18]. In accordance with the Mannheim Consensus [19],
measurement regions containing plaque and images with
insufficient quality were excluded from analysis. The ana-
lysed sequential images started and ended in end-diastole
containing one to three heart cycles. The per individual av-
erage CIMT (aCIMT) was calculated using mean CIMT
measures of both angles both of the right and left CCA. To
investigate intra-field worker variability, duplicate CIMT
exams were performed on two different days within 3
months after the first examination in a random sample
of eligible SAPALDIA3 participants (n = 165, age range
50–80 years, mean (SD) 62.1 (7.3) years for age, 40.6%
men, 59.4% women). The between-visit coefficient of vari-
ation for aCIMT was 3.98% (3.52–4.44), and the ICC 0.89
(0.87–0.93) [20].
Assessment of CVD disease and incidence
The definition of current CVD at SAPALDIA 2 was based
on reported doctor diagnosis of hypertension, heart disease,
myocardial infarction and stroke. In SAPALDIA 3 addi-
tional information was available on heart arrhythmias,
angina pectoris, and heart insufficiency/failure. Newly re-
ported CVD disease at SAPALDIA 3 was considered in-
cident CVD. Relevant cardiovascular treatment was con-
sidered medication for CVD, diabetes and hypercholester-
olaemia.
CVD risk factors
Blood pressure
BP was measured in the sitting position after a 10-minute
rest with an interval of at least 3 minutes (automatic
OMRON 705IT, OMRON HEALTHCARE, Kyoto, Japan)
in SAPALDIA 2 and SAPALDIA 3. The mean of both
systolic and diastolic BP measurements was calculated and
used for analyses (systolic mean BP, diastolic mean BP).
Blood lipids
Non-fasting cardio-metabolic biomarkers (glucose,
HBA1C, total cholesterol, LDL cholesterol, triglycerides
and hsCRP) were available for subjects in SAPALDIA 2.
Details on the treatment of blood samples are described
elsewhere [16, 21].
Anthropometric data
Body mass index (BMI, kg/m2), was calculated using
weight and height measured at the study centres in
SAPALDIA 2 and SAPALDIA 3.
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Smoking status
Never, former and current smokers were defined based on
reported smoking habits at the time of both surveys and in
the past. Pack years smoked before and in between follow-
ups was calculated for former and current smokers.
Family cardiovascular medical history
Participants were asked in SAPALDIA 3 if a first grade re-
lative had had a myocardial infarction or stroke before or
after the age of 60 years. The “family health questionnaire”
was filled out by participants at home and sent back, res-
ulting in a relatively high percentage of missing data (n =
965, 34%). Multivariate imputation was applied (STATA
impute) and a missing dummy variable was generated.
Menopausal status (as part of AGLA score)
A detailed women’s health questionnaire with data on men-
opausal status was filled out at home in SAPALDIA 2.
Post-menopause was defined based on the STRAW defin-
ition of 12 months cessation of menstruation or medically
induced menopause [22]. Menopausal status was missing
from 403 women (28%).
Heart risk scores
The low risk score algorithm of SCORE was used based
on data from SAPALDIA 2: age, smoking status, BP, cho-
lesterol by sex separately (www.escardio.org). The three
highest risk categories (>5%–9% n = 139, >10%–15% n
= 22 and >15% n = 1) were collapsed to one (>5%) for
power reasons. The AGLA score includes, in addition, dia-
betic status, HDL, LDL, triglycerides from SAPALDIA
2 and family CVD history taken from SAPALDIA 3
(www.agla.ch). The resulting ALGA score was divided
by four in pre-menopausal women. Two distinct variables
were calculated: AGLA-1 in all participants (n = 2812) us-
ing imputed data on family medical history and defining
women <= 50 years as pre-menopausal [23], if data was
missing, and AGLA-2 in subjects with complete data, only
(n = 1586). AGLA-2 was used in sensitivity analyses.
Statistical analyses
After exclusion of participants with missing outcome or ex-
posure data, 2,832 SAPALDIA participants were included
into the analyses (fig. 1). Average CIMT was log-trans-
formed because of a non-normal distribution. Descriptive
analyses of aCIMT and single risk factors were run by
sex. Age- and sex-adjusted mean CIMT were calculated
by Swiss language region (German-speaking: Basel, Da-
vos, Wald, Aarau; French-speaking: Payerne, Montana,
Geneva, and Italian-speaking: Lugano). Multi-level linear
regression analyses between CVD risk scores and aCIMT
were adjusted for study centre as random effect, only. A
second extended model was additionally adjusted for cardi-
ovascular risk factors not included in the score algorithms,
such as BMI, physical activity, pack-years and educational
status. Test for trend was based on the continuous scores,
investigating non-linear trends by introducing polynomials.
Sensitivity analyses were run: first, differentiating in CVD
healthy and CVD diagnosed participants based on reported
CVD treatment or CVD diagnoses at SAPALDIA 2 or
SAPALDIA 3, second using AGLA-2, and third, adjusting
for heart medication intake at SAPALDIA 3. The observed
differences in CIMT in SAPALDIA 3 by risk category, as
defined in SAPALDIA 2, are presented as % difference
of the geometric mean. The secondary analyses on the as-
sociation between AGLA-1 and CVD incidence between
SAPALDIA 2 and SAPALDIA 3 was estimated by mixed
effect logistic regression analyses adjusted for additional
health risks of disease (diabetes, COPD, lung emphysema,
and creatinine at SAPALDIA 2, pack years between
SAPALDIA 2 and SAPALDIA 3, and BMI at SAPALDIA
3), educational status and study centre as random variable.
Covariate inclusion was based on biological plausibility
and prior knowledge using a step-wise backward strategy
(significance level of 0.2). All analyses were performed for
the total sample and stratified by sex.
Thirdly, we ran path analyses to investigate the hypothesis
that cardiovascular risk factors indirectly affect CIMT via
the haemodynamic pathways, systolic and diastolic BP and
heart rate. Path analyses allow structural dependencies
among a set of covariates to be identified. Based on po-
tential causal relationships the pathway model analyses the
direct and indirect impact of model covariates on the out-
come of interest. (STATA pathreg) [24]. Significant stand-
ardised beta-regression coefficients depicted in figure 4
allow the relative magnitude of effects to be compared (sig-
nificance level of 0.05). All analyses were done in STATA
12 (www.stata.com/stata12).
Results
The SAPALDIA CIMT study population age ranged from
40–73 years in SAPALDIA 2 (mean 55.5, SD 8.0). The
mean follow-up time between SAPALDIA 2 and
SAPALDIA 3 was 8.3 years (SD 0.4). Prevalence of re-
ported doctor diagnosed cardiovascular disease was 21%
in SAPALDIA 2 and 53% in SAPALDIA 3, with a sig-
nificantly higher prevalence in men compared to women
(24.3% vs 17.5%; p <0.001). Furthermore, several risk
factors, such as high BP or smoking, were more prevalent
in SAPALDIA 3 as well as in men as compared to
SAPALDIA 2 and women, respectively (supplemental
table 1). The geometric mean (GM) of aCIMT was 0.728
mm (95% CI 0.723; 0.732). Men had a significantly thicker
aCIMT GM (0.746 mm, 95% CI 0.739; 0.753) than women
Figure 2
Association of AGLA-1 with aCIMT in SAPALDIA 3. ▬ Depicts
estimated %difference of the geometric mean (GM), ▌ confidence
interval of estimated %change. *** p-value <0.001, between risk
and reference category, α adjusted for study area (random effect).
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(0.710 mm, 95% CI 0.704; 0.716; p-value <0.001). Age-
and sex-adjusted geometric mean aCIMT were signific-
antly different in the language regions (German-: 0.726
mm; French-: 0.725; Italian-speaking: 0.742, p <0.001).
Analyses on potential bias by non-response showed that
non-responders to the women’s questionnaire were signi-
ficantly older (3.65 yr, 95% CI 4.56; 2.74, p-value <0.001),
of slightly higher BMI (0.75 unit BMI, 95% CI 1.25; 0.26,
p-value 0.003), but did not differ significantly compared
to responders with regard to systolic BP, smoking status,
total cholesterol, glucose and CVD disease at either survey
after age-adjustment. Non-responders to the family medic-
al questionnaire were significantly more often male (37%
male, 31% female, p-value 0.02) and, after adjustment for
sex, had significantly higher values for BMI (mean BMI 26
vs 25.5, p-value 0.02), heart rate (mean 70.5 vs 70, p-value
0.03), glucose (mean 5.8 vs 5.6, p-value 0.003) and pack
years (mean 18 vs 16.8, p-value 0.04).
A small percentage of the study population fell into a high
risk category in SAPALDIA 2 (table 1). Women were more
often assigned to lower AGLA-1 risk scores than men
(AGLA-1 <1%: 10% men and 40% women), while there
were small differences by sex in the high risk category
(AGLA-1 risk group >20%: 2.7% men, 2.4% women).
Figure 3
Association of SCORE with aCIMT in SAPALDIA 3. ▬ Depicts
estimated %difference of the geometric mean (GM), ▌ confidence
interval of estimated % change. *** p-value <0.001, between risk
and reference category, α adjusted for study area (random effect)
Figure 4
Path analyses: systolic blood pressure and carotid intima media
thickness.
Beta coefficients in blue: direct effect on systolic BP, in green:
indirect effect on CIMT, mutually adjusted and adjusted for physical
activity (non-significant impact on BP and CIMT); R2 = variance
explained by path model; sqrt(1–r2) = estimated error
Sex differences in SCORE were significant and consistent
across all risk groups.
The multivariate linear analyses yielded a significant posit-
ive association (figs 2 and 3). Between the AGLA-1 refer-
ence category and the highest risk category was a 22% dif-
ference in the GM corresponding to 0.16 mm, respectively
20% (0.15 mm) for the SCORE. Trend analyses showed an
exponential relationship (quadratic polynomial, y = α + βx
+ (-β)x2, test for trend: p-value 0.001), levelling out in the
highest categories. The associations were significantly pos-
itive in both sex (supplemental table 2) and remained un-
changed after adjustment for additional cardiovascular risk
(supplemental table 3).
Sensitivity analyses stratifying by participants who either
reported CVD or were under relevant treatment (CVD dis-
eased) and participants without CVD or treatment (CVD
healthy) at SAPALDIA 2 or SAPALDIA 3 did not differ
significantly to the main analyses (table 2), albeit a smaller
percentage change in aCIMT was found in CVD diseased
compared to CVD healthy subjects. Neither did the addi-
tional adjustment change the longitudinal correlation found
between the scores and CIMT (supplemental table 4). The
sensitivity analyses with the AGLA-2 score showed similar
strength and direction of association (supplemental table
3).
The logistic regression yielded significant positive asso-
ciations between AGLA-1 and CVD incidence during the
follow-up time (table 3). Women, in general, were at lower
odds of developing CVD. At SAPALDIA2 all pre-meno-
pausal women were assigned the lowest AGLA risk cat-
egory. Excluding these women, the results in postmeno-
pausal women were more similar to men.
Figure 4 presents the output path model of the path analysis
with the significant standardised beta-regression coeffi-
cients. Direct and indirect associations were found for all
endogenous variables of the path model and aCIMT. The
hypothesised haemodynamic pathway could be shown for
systolic BP (fig. 4). In this model only age yielded a higher
direct impact on aCIMT than systolic BP. Path-analyses of
other haemodynamic proxies (diastolic BP and heart rate)
showed less and non-significant direct impact on CIMT
(data not shown).
Discussion
We found the two CVD risk scores, AGLA and SCORE,
based on clinical SAPALDIA data from 2001/02, to be sig-
nificantly and positively associated with the CIMT data
measured approximately 10 years later, both in SAPALDIA
subjects with known CVD disease as well as in “CVD
healthy” subjects. Our findings are greatly in agreement
with other investigations, but in addition the analysis
demonstrates that cardiovascular risk scores, originally de-
veloped to estimate the risk of cardiovascular morbidity or
fatal events, also have a predictive power for early stage
disease, a time in which prevention is most effective. The
association was, however, not strictly linear. The increase
in CIMT levelled out in higher risk categories. Similarly,
we found significantly increased odds of newly diagnosed
CVD in higher risk categories, but the result was lower
than to be expected from the estimated score. Possibly, the
Original article Swiss Med Wkly. 2014;144:w14052
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high risk groups of 2001 underwent more personal life-
style modifications and received more therapeutic inter-
ventions compared to lower risk groups. A methodologic-
al explanation may be the exclusion of plaque images and
thereby aCIMT measures >1.5 mm. Furthermore, a healthy
Table 1: Prevalence of risk categories AGLA-1 and SCORE – in the SAPALDIA study population (≥50 years).
AGLA-1α n = 2,812 % Men
n = 1,393
Women
n = 1,439
10 yr risk <1% 742 26.4 9.83 42.41
10 yr risk 1%–2% 331 11.8 14.61 9.03
10 yr risk 2%–5% 728 25.9 31.67 20.29
10 yr risk 5%–10% 600 21.3 26.32 16.52
10 yr risk 10%–20% 338 12 14.82 9.31
10 yr risk >20% 73 2.6 2.75 2.45
SCOREβ n = 2,830
10 yr risk <1% 1,316 46.5 25.05 67.2
10 yr risk 1% 703 24.8 26.92 22.79
10 yr risk 2% 354 12.5 19.96 5.28
10 yr risk 3%–4% 297 10.5 17.3 3.89
10 yr risk >5% 162 5.72 10.77 0.83
α AGLA-1 corresponds to the adapted PROCAM cardiovascular risk score by the Swiss Society of Cardiology (Arbeitsgruppe Lipide und Atherosklerose)
β SCORE corresponds to the ESC heart risk score
Table 2: Association of AGLA-1 and SCORE with aCIMT in SAPALDIA 3 by doctor diagnosed CVD status in SAPALDIA 2 and SAPALDIA 3.
CVD
healthy study populationδ
CVD
diagnosed study populationδ
n = 1,249 n = 1,563
AGLA-1α Estimated %
differenceμ
(95% CI) p-value Estimated %
differenceμ
(95% CI) p-value
10 yr risk <1% Reference Reference
10 yr risk 1%–2% 8 (5.7; 10.2) <0.001 4.5 (–2.4; 11.4) 0.205
10 yr risk 2%–5% 11 (9.1; 13.0) <0.001 4.6 (–0.2; 9.3) 0.059
10 yr risk 5%–10% 17.6 (15.2; 20.0) <0.001 11.6 (6.9; 16.3) <0.001
10 yr risk 10%–20% 24.2 (20.7; 27.7) <0.001 11.4 (6.4; 16.4) <0.001
10 yr risk >20% 30.3 (19.9; 40.6) <0.001 11.6 (3.9; 19.3) 0.003
SCOREβ n = 1,256 n = 1,576
10 yr risk <1% Reference Reference
10 yr risk 1% 8.4 (6.5; 10.3) <0.001 5.1 (3.0; 7.1) <0.001
10 yr risk 2% 13.7 (10.9; 16.5) <0.001 9.4 (7.0; 11.8) <0.001
10 yr risk 3%–4% 19.7 (16.0; 23.4) <0.001 14.6 (12.1; 17.0) <0.001
10 yr risk >5% 24.7 (19.2; 30.2) <0.001 16.6 (13.6; 19.6) <0.001
α AGLA-1 corresponds to the adapted PROCAM cardiovascular risk score by the Swiss Society of Cardiology (Arbeitsgruppe Lipide und Atherosklerose)
β SCORE corresponds to the ESC heart risk score
δ CVD healthy/β CVD diseased: based on reported doctor diagnosis of hypertension, heart disease, myocardial infarction, angina pectoris, heart insufficiency or stroke at
SAPALDIA 2 or SAPALDIA 3.
μ The estimated % difference between the respective risk group and the reference with respect of the geometric mean CIMT (0.73 mm).
Table 3: Odds of developing a cardiovascular disease over the follow-up time from SAPALDIA 2 (2001/02) to SAPALDIA 3 (2010/11) by AGLA risk score in SAPALDIA 2,
stratified by sex.
All n = 2,795 Men n = 1,371
AGLA-1α Odds ratioβ 95% CI p-value Odds ratioβ 95% CI p-value
10 yr risk <1% Ref. Ref.
10 yr risk 1%–2% 1.08 0.80; 1.46 0.603 1.45 0.85; 2.46 0.175
10 yr risk 2%–5% 1.33 1.06; 1.68 0.015 2.27 1.41; 3.65 0.001
10 yr risk 5%–10% 1.93 1.51; 2.45 0.000 2.65 1.63; 4.30 0.000
10 yr risk 10%–20% 2.21 1.66; 2.93 0.000 3.18 1.89; 5.36 0.000
10 yr risk >20% 3.71 2.24; 6.13 0.000 8.70 3.85; 19.69 0.000
AGLA-1α Women n = 1,424 Women, post-menopausal at SAPALDIA 2, n = 565
10 yr risk <1% Ref. Ref.
10 yr risk 1%–2% 1.10 0.72; 1.68 0.651 3.18 1.22; 8.28 0.018
10 yr risk 2%–5% 0.95 0.69; 1.30 0.731 2.07 0.85; 5.02 0.109
10 yr risk 5%–10% 1.92 1.40; 2.65 0.000 4.61 1.87; 11.34 0.001
10 yr risk 10%–20% 2.09 1.40; 3.11 0.000 4.89 1.89; 12.61 0.001
10 yr risk >20% 2.14 1.06; 4.30 0.033 5.67 1.60; 20.15 0.007
α AGLA-1 corresponds to the adapted PROCAM cardiovascular risk score by the Swiss Society of Cardiology (Arbeitsgruppe Lipide und Atherosklerose)
β adjusted for education, chronic bronchitis, smoking status at SAP3, creatinine, BMI at SAP3 and study area as random variable
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selection bias is possible, leading to an underestimation of
the risk association.
Vascular aging, a normal physiological process, can be ac-
celerated by exposure to risk factors. We showed signific-
ant direct impact on CIMT by single risk factors, as well as
indirect effects. Age was the determinant with the largest
impact on intima media thickness in the path analyses. In-
cluding follow-up time into the analysis did not change the
results, indicating that the factor age is more than just “time
passing”. It stands for the exposure time to risk factors, cor-
responding cellular processes and pathomechanisms. Sex,
another non-modifiable risk factor, proved to be signific-
antly associated with aCIMT, as well as with the prevalen-
ce of risk factors and CVD. Consistent with literature, fe-
male sex was associated with a thinner aCIMT. However,
our sensitivity analyses in post-menopausal women in
SAPALDIA 2 showed a comparable risk of CVD incidence
to that of men, in line with the delayed occurrence of clin-
ical CVD in women [25, 26]. Menopause-related hormonal
or metabolic changes add to and accentuate the overall car-
diovascular risk [27, 28].
Hypertension is a CVD risk factor with a direct impact on
CIMT [29], and is therefore included in all cardiovascu-
lar risk scores, next to life-style risks and age. The later
risk factors are shared by high BP and CIMT, but very few
studies have looked into this complex interplay [30]. The
presented path analysis supports the hypothesised indirect
effects of life-style risks on CIMT via haemodynamic path-
way. Considering the high prevalence of many of these risk
factors and prevalent under-treatment of high BP or non-
compliance [31, 32], primary and secondary prevention
must be strengthened. We assumed a uni-directional caus-
al association, despite some indications of a bi-directional
association for functional vascular parameters and hyper-
tension [33]. Life-style risk factors will most certainly also
impact via the inflammatory pathway [30, 34]. Some evid-
ence for an inflammatory pathway in pathological vascular
aging can be deduced from the impact of the inflammat-
ory proxy obesity (BMI). We found no association between
hsCRP and aCIMT, possibly due to a high intra-individual
variability of CRP, and CRP being rather an acute biomark-
er.
The incremental value of CIMT to the general risk score
assessment in therapeutic settings has been disputed, even
though combining score and CIMT has been shown to re-
classify patients’ risk [8, 9]. Inconsistency in the findings
partly relates to different study designs. Although adding
CIMT to the Framingham risk score in a general population
did not show an improvement of the risk prediction [35],
other studies investigating specific sub-groups, such as wo-
men [36] or hypertensive subjects [37] have observed an
additive value. Based on the current knowledge, the ESC
guidelines 2012 value the added information by carotid ul-
trasound examinations beyond the assessment of tradition-
al risk factors to help in decision-making about the neces-
sity medical treatment [38]. The predictive value of plaque
compared to intimal medial thickening is also subject of
discussion. Plaques, corresponding strongly to the athero-
genic process, have been found to better predict vascular
age [39] and cardiovascular events, especially stroke, and
therapy success in individuals than CIMT alone [40, 41].
Maximal IMT also showed improved cardiovascular risk
classifications [9]. On a population level, CIMT seems to
be a very good estimator of cardiovascular risk, even more
since CIMT combines vascular structural changes due to
haemodynamic and atherogenic risk factors [11, 42]. CIMT
is also known to be predictive of atherosclerosis in other
blood vessels [43], while plaques, beyond being methodo-
logically more time consuming to ascertain, are often loc-
alised pathologies. In view of the public health effort, the
identification of early stage disease on a population-level
must be a major aim.
We present first data of a large Swiss population-based
study on CIMT. While our presented analysis was not a
primary aim from the start of the cohort in 1991, which
could potentially be viewed as a limitation, the value and
strength of epidemiological cohorts lies in collecting indi-
vidual and environmental data over the life course and to be
able to investigate future relevant study questions. Thus our
prospectively collected cardiovascular biomarkers and risk
factors, and the high quality standards of the carotid artery
ultrasound data allowed us to successfully characterise the
cardiovascular risk profile of the SAPALDIA participants
and confirm the predictive association of locally applied
risk scores with vascular health indicators in Switzerland.
Having focused on CIMT without an assessment of the
total plaque area (TPA), we could, however, not compare
the two indicators, CIMT and TPA. Among thelimiting
factors of longitudinal studies is loss to follow-up with a
risk of a healthy selection; a concern in our population
as well. The study design did not allow for fasting blood
samples limiting the use of certain blood lipids and gluc-
ose levels. Since cardiovascular health history was assessed
in more detail in SAPALDIA 3 compared to SAPALDIA
2, an overestimation of CVD incidence at SAPALDIA 3
is possible, thereby overestimating the association with the
AGLA score. For the sensitivity analyses, however, we
expect that by excluding subjects classified “CVD dis-
eased” in SAPALDIA 3, one would have excluded the par-
ticipants, which the earlier SAPALDIA 2 questionnaire on
cardiovascular disease might have missed. Moreover, some
covariates were self-reported and misclassification cannot
be excluded. Misclassification would not be expected to be
differential. Missing data, such as data on family CVD his-
tory, could have led to error; although sensitivity analyses
yielded robust results and no indication of bias.
In conclusion, this first population-based Swiss study on
CIMT confirms the longitudinal association between car-
diovascular risk factors and intima media thickening, both
in “CVD healthy” and in participants with diagnosed CVD.
On a population-level, CIMT adds to a more robust estim-
ation of the population at risk for early stage disease, rel-
evant for prevention policies and health system planning.
Our study supports the clinical use of risk scores not only
to estimate risk of disease incidence, but also early vascu-
lar pathology. The haemodynamic pathway analysis under-
scores that optimal haemodynamics are of high clinical and
public health concern. Combining risk scores with CIMT
measures and visualising the vascular impact may constitu-
te an additional motivational argument in individual treat-
ment settings.
Original article Swiss Med Wkly. 2014;144:w14052
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Supplemental tables
Supplemental table 1: Cardiovascular risk profile in the study population in SAPALDIA 2 and SAPALDIA 3.
All n = 2832 Men n = 1392 Women n = 1438
SAPALDIA 2 Mean SD Mean SD Mean SD
Age (yr) 55.5 8.0 55.6 8.0 55.5 8.1
BMI (kg/m2)*** 25.7 4.0 26.5 3.4 25.0 4.3
Systolic blood pressure (mm Hg)*** 127.4 19.1 133.4 17.6 121.9 18.8
Diastolic blood pressure (mm Hg)*** 80.4 10.9 83.4 10.6 77.6 10.3
Heart rate 70.0 10.3 69.3 10.9 70.7 9.6
Total Cholesterol 6.1 1.1 6.1 1.1 6.2 1.1
HDL*** 1.5 0.4 1.3 0.4 1.7 0.4
Triglycerides*** 1.8 1.1 2.1 1.3 1.6 0.9
Glucose*** 5.6 1.4 5.8 1.6 5.4 1.0
Pack years*** 10.2 17.3 12.7 17.9 6.5 11.9
% % %
Educational statusα,***
Low
5.5 3.2 7.8
Middle 66.2 59.5 72.7
High 28.3 37.3 19.5
Smoking status***
Never
43.9 35.4 52.2
Former 35.3 42.0 28.8
Current 20.8 22.6 19.1
Physical Activityβ,***
Low
36.4 30.3 42.3
Middle 33.4 32.0 34.8
High 30.2 37.7 22.9
Diabetes, physician diagnosed*** 2.2 3.4 1.0
Hypertension, physician diagnosed*** 17.1 20.0 14.2
CVDγ, physician diagnosed*** 20.9 24.3 17.5
SAPALDIA 3 Mean SD Mean SD Mean SD
CIMT average (mm) 0.74 0.13 0.76 0.13 0.72 0.12
BMI (kg/m2)*** 26.3 4.3 27.0 3.7 25.5 4.7
Systolic blood pressure (mm Hg)*** 135.3 18.7 138.3 17.7 132.4 19.3
Diastolic blood pressure (mm Hg)*** 79.3 10.3 80.9 10.3 77.6 10.0
Pack years*** 13.0 20.6 16.4 23.1 9.0 16.4
% % %
Smoking Status***
Never
43.1 34.8 51.3
Former 41.8 49.4 34.4
Current 15.1 15.8 14.4
CVDδ, physician diagnosed*** 54.9 59.9 50.0
α Educational status: based on reported highest educational degree; β physical activity: reported hours of vigorous physical activity; γ CVD in SAPALDIA 2: doctor diagnosis
of hypertension, heart disease, myocardial infarction or stroke; δ CVD in SAPALDIA 3: doctor diagnosis same as SAPALDIA 2 plus arrhythmias, angina pectoris, heart
insufficiency; difference by gender (chi2, ANOVA) *** p<0.001
Supplemental table 2: Association of AGLA-1 and SCORE with average carotid intima media thickness in SAPALDIA 3 by sex.
Men n = 1383 Women n = 1429
AGLA Estimated %
differenceβ
95% CI p-value Estimated %
differenceβ
95% CI p-value
<1% 10-year risk Reference
1%‒2% 6.90 3.32 10.40 <0.001 5.90 3.23 8.50 <0.001
2%‒5% 11.90 8.81 15.10 <0.001 10.10 8.16 12.10 <0.001
5%‒10% 16.70 13.53 19.90 <0.001 16.30 14.17 18.40 <0.001
10%‒20% 21.30 17.75 24.80 <0.001 19.60 17.01 22.20 <0.001
>20% 20.00 14.19 25.90 <0.001 23.20 18.41 27.90 <0.001
SCORE
<1% 10-year risk Reference
1% 4.70 2.32 7.00 <0.001 9.20 7.40 11.00 <0.001
2% 9.90 7.36 12.40 <0.001 17.00 13.68 20.40 <0.001
3%‒4% 15.60 12.97 18.20 <0.001 21.70 17.84 25.60 <0.001
>5% 18.50 15.41 21.60 <0.001 26.60 18.37 34.80 <0.001
β The estimated % difference refers to the difference from the geometric mean CIMT (0.728 mm)
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Supplemental table 3: Association between AGLA-1 and SCORE and aCIMT, adjusted for BMI, pack years, physical activity and educational status at SAPALDIA 2.
AGLA-1α β-coeff.β 95% CI p-value
<1% 10-year risk Reference
1%‒2% 6.0 4.0 8.0 <0.001
2%‒5% 10.2 8.6 11.8 <0.001
5%‒10% 15.0 13.3 16.7 <0.001
10%‒20% 19.0 17.0 21.1 <0.001
>20% 20.1 16.4 23.8 <0.001
SCOREα β-coeff.β 95% CI p-value
<1% 10-year risk References
1% 6.5 5.1 7.9 <0.001
2% 11.0 9.2 12.9 <0.001
3%‒4% 16.1 14.1 18.1 <0.001
>5% 18.2 15.5 20.8 <0.001
α For BMI, pack years, physical activity and educational status, study centre (random effect) at SAPALDIA 2; β the estimated % difference refers to the difference from the
geometric mean CIMT (0.728 mm)
Supplemental table 4: Association between AGLA-1 and aCIMT, adjusted for heart medication intake at SAPALDIA 3.
AGLA-1 risk score* β-coeff. 95% CI p-value
10-year risk <1%
1%‒2% 0.065 0.046 0.085 0.000
2%‒5% 0.110 0.095 0.126 0.000
5%‒10% 0.162 0.146 0.179 0.000
10%‒20% 0.202 0.183 0.222 0.000
>20% 0.213 0.176 0.249 0.000
* Adjusted for heart medication intake at SAPALDIA 3 and study area as random effect
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Figures (large format)
Figure 1
Flow chart. SAPALDIA – follow-ups and timing of data collection of cardiovascular risk factors and CIMT assessment.
Figure 2
Association of AGLA-1 with aCIMT in SAPALDIA 3. ▬ Depicts estimated %difference of the geometric mean (GM), ▌ confidence interval of
estimated %change. *** p-value <0.001, between risk and reference category, α adjusted for study area (random effect).
Original article Swiss Med Wkly. 2014;144:w14052
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 11 of 12
Figure 3
Association of SCORE with aCIMT in SAPALDIA 3. ▬ Depicts estimated %difference of the geometric mean (GM), ▌ confidence interval of
estimated % change. *** p-value <0.001, between risk and reference category, α adjusted for study area (random effect)
Figure 4
Path analyses: systolic blood pressure and carotid intima media thickness.
Beta coefficients in blue: direct effect on systolic BP, in green: indirect effect on CIMT, mutually adjusted and adjusted for physical activity (non-
significant impact on BP and CIMT); R2 = variance explained by path model; sqrt(1–r2) = estimated error
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